EN DE
Watch Madame Bioscience Public Company Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Madame Bioscience Public Company Limited (MADAME) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Madame Bioscience Public Company Limited stock THB 1.25, price THB 1.20, upside +4.2%, quality 49 out of 100. Rating: fairly valued. Calculated from audited financials with 8 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive TH

MB Madame Bioscience Public Company Limited logo Thin data Nov 4, 2026

Madame Bioscience Public Company Limited

MADAME · BK
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Profit last quarter +117% vs. a year ago.
Fair value 1.25 THB · Fairly valued
Quality 49/100
Loss over the last twelve months · -8.9% net margin (TTM) · fiscal year 2025 3.1%
Mixed vs. peers (5/11)
Weak Growth (revenue 3y −12.8 %/yr in THB)
Negative free cash flow
Narrow moat 26/100 · thin data
Thin data
Watch Madame Bioscience Public Company Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

6.60 THB 0.4300 THB Fair Value 1.25 THB Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range 0.4300 THB – 6.60 THB · fair‑value band 0.9300 THB – 1.56 THB · the 1.20 THB price screens below the 1.25 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Madame Bioscience Public Company in your weekly email

Every Wednesday you see whether Madame Bioscience Public Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Madame Bioscience Public Company Limited, together with its subsidiaries, engages in the food business in Thailand. It operates through Packaging Business, Retail Sales of Cosmetics, Food Business, and Other Business segments.

Show moreShow less

The company offers various food products, including frozen processed and ready-to-eat food, chilled food, plant-based food, hemp food, processed food, and sauces under the Kitchen Plus and Look Chin Tip brands.

It also provides flexible packaging, polyethylene terephthalate bottles, and food packaging trays for packaged food and beverages.

In addition, the company engages in the manufacture and sale of plastic packaging, seafood, and processed meat; retail sale of cosmetics; advertising rental services in gas stations; restaurant business; network marketing; and trading activities.

The company was formerly known as Global Consumer Public Company Limited and changed its name to Madame Bioscience Public Company Limited in July 2025. Madame Bioscience Public Company Limited was founded in 1987 and is headquartered in Bangkok, Thailand.

Stock analysis

Madame Bioscience Public Company Limited (MADAME) currently trades at 1.20 THB, while our model-based Fair Value estimate is 1.25 THB, so the stock looks roughly fairly valued today (gap 4.0%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 2.27 THB per share, and 3 of the 8 models we run sit above the 1.20 THB price.

Bear case: the Asset-Based group reads lowest at 0.2600 THB, and 5 of the 8 models stay below the price. Data coverage for this calculation is low.

Scenario range: 0.9300 THB (bear) to 1.56 THB (bull), the price of 1.20 THB sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Consumer Defensive sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Madame Bioscience Public Company Limited reported revenue of 1.5B THB in FY2025 versus 1.9B THB in FY2021, a compound −5.6%/yr. Reported net income was 45.8M THB in FY2025.

Key figures

Market cap 969M THB (≈ $29.0M) Micro · P/S ratio 0.54 · EPS (TTM) −0.1900 THB · Net margin −8.9% · Return on equity −17.3% · Return on assets (EBIT) −9.5% (5-year average) · Operating margin 6.9% · Revenue (TTM) 1.6B THB.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 26 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 179% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −1% fair-value upside, at 4%, MADAME screens cheaper than that median.

Fair Value models

Bear 0.9300 THB Fair Value 1.25 THB Bull 1.56 THB
Price 1.20 THB · Upside +4.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings 1.78 THB 2.27 THB 3.09 THB 74
Residual Income 0.6900 THB 0.7100 THB 0.7500 THB 73
Graham-Dodd 0.3900 THB 0.4700 THB 0.5300 THB 65
All 8 models by family
DCF Models
Owner Earnings 1.78 THB 2.27 THB 3.09 THB 74
Earnings-Based
Graham-Dodd 0.3900 THB 0.4700 THB 0.5300 THB 65
Multiples
P/E Multiple 0.9300 THB 1.25 THB 1.56 THB 63
P/S Multiple 0.7200 THB 0.9600 THB 1.20 THB 58
P/B Multiple 1.33 THB 1.77 THB 2.21 THB 55
Asset-Based
NCAV (Graham) 0.2000 THB 0.2600 THB 0.3900 THB 54
Economic Profit
Residual Income 0.6900 THB 0.7100 THB 0.7500 THB 73
Growth Earnings
Growth-Adj P/E 0.6600 THB 0.9400 THB 1.22 THB 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 44
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 16
Do the profits arrive as real cash?
Financial strength 53
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 82
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 81
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−30.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.2% (2021) → −14.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Watch MADAME, get fair value alerts →

Compare Madame Bioscience Public Company Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 627 stocks

Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside +4.2% · Above median
Profitability
Return on assets 3.5% · Below median
Net margin (12 months) −8.9% · Bottom 25%
Operating margin (12 months) 6.9% · Above median
Growth and dividend
Revenue growth (quarter YoY) 14.6% · Above median
Balance sheet
Debt / equity 0.19× · Above median

Valuation Multiplesvs Packaged Foods median · lower = cheaper

P/B 1.30× · Cheaper than median
P/S (12 months) 0.61× · Cheaper than median
PEG 2.50× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)39 · sector 36
FUTURE (revenue growth)73 · sector 25
PAST (return on equity)0 · sector 31
HEALTH (low debt)91 · sector 96
DIVIDEND (yield)0 · sector 55

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Wilmar International Limited F34 2.97 SGD 4.93 SGD +66% vs MADAME
Inner Mongolia Yili Industrial Group 600887 ¥31.14 ¥41.84 +34% vs MADAME
The Kraft Heinz Company KHC $24.61 $29.20 +19% vs MADAME
Foshan Haitian Flavouring and Food Company 603288 ¥35.26 ¥39.22 +11% vs MADAME
General Mills, Inc GIS $35.51 $35.30 −1% vs MADAME
Danone S.A BN €67.66 €50.65 −25% vs MADAME
Nestlé S.A NESN CHF 86.13 CHF 59.51 −31% vs MADAME
Kerry Group KRZ €97.15 €60.33 −38% vs MADAME
Nestlé India Limited NESTLEIND ₹1,298 ₹724.74 −44% vs MADAME
Yihai Kerry Arawana Holdings 300999 ¥26.14 ¥12.21 −53% vs MADAME

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Madame Bioscience Public Company Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Madame Bioscience Public Company Limited Fair Value". https://www.fairvalue-calculator.com/stock/MADAME

Frequently asked questions

Is Madame Bioscience Public Company Limited (MADAME) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 1.25 THB versus a price of 1.20 THB, about +4% upside (fairly valued).
What is the fair value of MADAME?
Our model-based fair value for Madame Bioscience Public Company Limited is 1.25 THB (as of Nov 4, 2026), built from audited fundamentals. The current price: 1.20 THB.
What is the quality score of MADAME?
Madame Bioscience Public Company Limited has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Madame Bioscience Public Company Limited (MADAME)?
Our model-based price target is the fair value of 1.25 THB (as of Nov 4, 2026) from 8 valuation models. Cautious scenario 0.9300 THB, optimistic scenario 1.56 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Madame Bioscience Public Company Limited stock forecast for 2026?
Our models put fair value at 1.25 THB, about +4% upside versus a price of 1.20 THB (fairly valued). Cautious scenario 0.9300 THB, optimistic scenario 1.56 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Madame Bioscience Public Company Limited (MADAME)?
Madame Bioscience Public Company Limited reported trailing-twelve-month revenue of about 1.6B THB (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Madame Bioscience Public Company Limited (MADAME)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Madame Bioscience Public Company Limited it is 1.25 THB per share (as of Nov 4, 2026), against a price of 1.20 THB. It is the blended result of 8 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Madame Bioscience Public Company Limited stock overvalued or undervalued in 2026?
As of Nov 4, 2026, MADAME trades below its calculated fair value: price 1.20 THB, fair value 1.25 THB, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MADAME?
No. The price is what the market pays today (1.20 THB); the fair value is what the company's own numbers justify (1.25 THB). For Madame Bioscience Public Company Limited the two are 0.0500 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Madame Bioscience Public Company Limited worth?
The market values Madame Bioscience Public Company Limited at about 969M THB (market capitalisation, as of Nov 4, 2026). Per share that is 1.20 THB; our models calculate a fair value of 1.25 THB per share.
What do the bullish and bearish scenarios say about MADAME?
Our models span a range for Madame Bioscience Public Company Limited: cautious scenario 0.9300 THB, base 1.25 THB, optimistic 1.56 THB per share (as of Nov 4, 2026, price 1.20 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MADAME?
The PEG ratio of Madame Bioscience Public Company Limited is 2.50 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Madame Bioscience Public Company Limited (MADAME)?
Balance-sheet figures for Madame Bioscience Public Company Limited (as of Nov 4, 2026): return on equity −17.3%, debt of 0.19 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is MADAME from its 52-week high?
Madame Bioscience Public Company Limited trades at 1.20 THB, at its 52-week high of 1.20 THB and 179% above the low of 0.4300 THB (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 1.25 THB is for.
Which stocks are comparable to Madame Bioscience Public Company Limited?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Madame Bioscience Public Company Limited stock attractive at the current price?
The data as of Nov 4, 2026: price 1.20 THB, calculated fair value 1.25 THB (+4%), Quality Score 49/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MADAME calculated?
We run Madame Bioscience Public Company Limited through 8 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1.25 THB builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Madame Bioscience Public Company Limited currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Madame Bioscience Public Company Limited (MADAME)?
The closing price on Nov 9, 2026 was 1.20 THB. Our model-based fair value is 1.25 THB, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Madame Bioscience Public Company Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Madame Bioscience Public Company Limited

How large is the market capitalisation of Madame Bioscience Public Company Limited (MADAME)?
The market capitalisation of Madame Bioscience Public Company Limited is 969M THB (≈ $29.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Madame Bioscience Public Company Limited (MADAME)?
The price-to-sales ratio of Madame Bioscience Public Company Limited is 0.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Madame Bioscience Public Company Limited (MADAME)?
Earnings per share at Madame Bioscience Public Company Limited are −0.1900 THB. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Madame Bioscience Public Company Limited (MADAME)?
The net margin of Madame Bioscience Public Company Limited is −8.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Madame Bioscience Public Company Limited (MADAME)?
The return on equity (ROE) of Madame Bioscience Public Company Limited is −17.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Madame Bioscience Public Company Limited (MADAME)?
On an EBIT basis the return on assets of Madame Bioscience Public Company Limited is −9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Madame Bioscience Public Company Limited (MADAME)?
The operating margin of Madame Bioscience Public Company Limited is 6.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Madame Bioscience Public Company Limited (MADAME)?
Revenue at Madame Bioscience Public Company Limited is growing +14.6% versus a year earlier (3y avg −12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Madame Bioscience Public Company Limited (MADAME)?
Earnings per share at Madame Bioscience Public Company Limited are growing +117% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Madame Bioscience Public Company Limited (MADAME) generate?
The free cash flow of Madame Bioscience Public Company Limited is −4.6M THB (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Madame Bioscience Public Company Limited (MADAME) carry?
The net debt of Madame Bioscience Public Company Limited is 60.0M THB (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Madame Bioscience Public Company Limited in the live analysis

One click puts Madame Bioscience Public Company Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.